The announcement is strange. It is not powered for efficacy so the results don’t mean much. Similarly, it is not clear how they measured response as they acknowledge the need for confirmatory scans among trial participants. Many of the criteria for measuring a response to treatment rests on scan measurements so it is unclear how they have decided there was a partial response or not.
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer, page-12
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.010(6.67%) |
Mkt cap ! $41.21M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $8.44K | 53.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 94946 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 169219 | 2 |
View Market Depth
| Last trade - 10.13am 07/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |